ID1 and cancer: Concluding from this research, radiolabeled anti-id VHHs generate strong therapeutic efficacy against multiple myeloma in the MRD stage, which suggests that radiolabeled anti-id VHHs are valuable therapeutic agents to prevent cancer relapse in multiple myeloma patients.